Oncology · Phase III

Top sponsors

• AstraZeneca 75 programs
• Chinese Academy of 70 programs
• HOFFMANN-LA ROCHE 68 programs
• MSD Merck Sharp 56 programs
• First People's Hospital 53 programs
• Ningbo Cancer Hospital 44 programs
• United Therapeutics Europe 43 programs
• Anaxis Pharma 37 programs
• AstraZeneca 37 programs
• Novartis India 32 programs
• George Institute for 29 programs
• Takeda 28 programs

1. UC-GIG-2408

   Ningbo Cancer Hospital

   Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

   phase 3 · small molecule · active

   1 trial →

2. UC-GIG-2410

   Ningbo Cancer Hospital

   Stage III colorectal cancer

   phase 3 · small molecule · active

   1 trial →

3. UC-GTG-2301

   Ningbo Cancer Hospital

   Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

   phase 3 · small molecule · active

   1 trial →

4. UC-GTG-2306

   Ningbo Cancer Hospital

   Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

   phase 3 · small molecule · active

   1 trial →

5. UC-IMM-2101

   Ningbo Cancer Hospital

   Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

   phase 3 · small molecule · active

   1 trial →

6. UGN-102 (Mitomycin)

   Lacuna Pharma Pty Ltd

   Non-Muscle Invasive Bladder Cancer

   phase 3 · small molecule · active

   1 trial →

7. UGN-103 (Mitomycin)

   Lacuna Pharma Pty Ltd

   Nonmuscle Invasive Bladder Cancer

   phase 3 · small molecule · active

   1 trial →

8. UGN-104

   Lacuna Pharma Pty Ltd

   Low-grade Upper Tract Urothelial Cancer

   phase 3 · small molecule · active

   1 trial →

9. URONCOR 06-24

   The George Institute

   Prostate Cancer

   phase 3 · small molecule · active

   1 trial →

10. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 · small molecule · completed

    5 trials →

11. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 · mab · terminated

    1 trial →

12. Unesbulin

    PTC Therapeutics International Limited

    Leiomyosarcoma

    phase 3 · small molecule · terminated

    1 trial →

13. Unesbulin

    PTC THERAPEUTICS, INC.

    Leiomyosarcoma

    phase 3 · small molecule · terminated

    2 trials →

14. V503-021

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 · small molecule · active

    1 trial →

15. V940-002

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

16. V940-007

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 · small molecule · active

    1 trial →

17. V940-009

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

18. VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 3 · other · active

    1 trial →

19. VERDYE 5 mg/ml poeder voor oplossing voor injectie

    Disc Medicine

    Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)

    phase 3 · small molecule · active

    1 trial →

20. VS-6766-301

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 · small molecule · active

    1 trial →

21. Vandetanib

    Sanofi Pasteur

    Non Small Cell Lung Cancer

    phase 3 · small molecule · completed

    1 trial →

22. Vandetanib

    Sanofi Pasteur

    Locally Advanced or Metastatic Medullary Thyroid Cancer

    phase 3 · small molecule · completed

    1 trial →

23. Vectibix 20 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer

    phase 3 · small molecule · active

    1 trial →

24. Vemurafenib

    Hoffmann-La Roche

    Malignant Melanoma

    phase 3 · small molecule · completed

    2 trials →

25. Venetoclax

    AbbVie

    Chronic Lymphocytic Leukemia

    phase 3 · small molecule · active

    1 trial →

26. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 · small molecule · active

    1 trial →

27. Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 3 · small molecule · active

    1 trial →

28. Venetoclax 400

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia

    phase 3 · small molecule · active

    1 trial →

29. Ventoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 3 · small molecule · active

    1 trial →

30. Verum acupuncture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 3 · other · active

    1 trial →

31. Vincristine Sulfate Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult Acute Lymphoblastic Leukemia

    phase 3 · small molecule · active

    1 trial →

32. Vinflunine

    Bristol-Myers Squibb

    Stomach Cancer

    phase 3 · small molecule · terminated

    1 trial →

33. Virulizin®

    Aptose Biosciences

    Pancreatic Cancer

    phase 3 · small molecule · completed

    1 trial →

34. Volrustomig

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma

    phase 3 · small molecule · active

    1 trial →

35. WO29637

    Hoffmann-La Roche

    Renal Cell Carcinoma

    phase 3 · small molecule · completed

    1 trial →

36. WO41535

    Hoffmann-La Roche

    High-risk hepatocellular carcinoma (HCC)

    phase 3 · small molecule · active

    1 trial →

37. WO41554

    Hoffmann-La Roche

    HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation

    phase 3 · small molecule · active

    1 trial →

38. WO41994

    Hoffmann-La Roche

    Renal cell carcinoma (RCC)

    phase 3 · small molecule · active

    1 trial →

39. WO42633

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 · small molecule · active

    1 trial →

40. WO45654

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 · small molecule · active

    1 trial →

41. WO46069

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 · small molecule · active

    1 trial →

42. XPORT-DLBCL-30

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 · small molecule · active

    1 trial →

43. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 · small molecule · terminated

    1 trial →

44. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 · small molecule · active

    1 trial →

45. Xtandi - soft capsules for Castration resistant prostate c…

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 · small molecule · active

    1 trial →

46. YO29232

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    phase 3 · small molecule · completed

    1 trial →

47. YO42137

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 · small molecule · active

    1 trial →

48. YiQiFang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 3 · small molecule · completed

    2 trials →

Frequently asked questions